BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 19401692)

  • 1. Activation of Wnt/beta-catenin signalling pathway induces chemoresistance to interferon-alpha/5-fluorouracil combination therapy for hepatocellular carcinoma.
    Noda T; Nagano H; Takemasa I; Yoshioka S; Murakami M; Wada H; Kobayashi S; Marubashi S; Takeda Y; Dono K; Umeshita K; Matsuura N; Matsubara K; Doki Y; Mori M; Monden M
    Br J Cancer; 2009 May; 100(10):1647-58. PubMed ID: 19401692
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The up-regulation of type I interferon receptor gene plays a key role in hepatocellular carcinoma cells in the synergistic antiproliferative effect by 5-fluorouracil and interferon-alpha.
    Oie S; Ono M; Yano H; Maruyama Y; Terada T; Yamada Y; Ueno T; Kojiro M; Hirano K; Kuwano M
    Int J Oncol; 2006 Dec; 29(6):1469-78. PubMed ID: 17088986
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interferon-alpha and 5-fluorouracil combination therapy after palliative hepatic resection in patients with advanced hepatocellular carcinoma, portal venous tumor thrombus in the major trunk, and multiple nodules.
    Nagano H; Miyamoto A; Wada H; Ota H; Marubashi S; Takeda Y; Dono K; Umeshita K; Sakon M; Monden M
    Cancer; 2007 Dec; 110(11):2493-501. PubMed ID: 17941012
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of hepatocellular carcinoma with major portal vein thrombosis by combined therapy with subcutaneous interferon-alpha and intra-arterial 5-fluorouracil; role of type 1 interferon receptor expression.
    Ota H; Nagano H; Sakon M; Eguchi H; Kondo M; Yamamoto T; Nakamura M; Damdinsuren B; Wada H; Marubashi S; Miyamoto A; Dono K; Umeshita K; Nakamori S; Wakasa K; Monden M
    Br J Cancer; 2005 Sep; 93(5):557-64. PubMed ID: 16106266
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activation of hepatic stem cell marker EpCAM by Wnt-beta-catenin signaling in hepatocellular carcinoma.
    Yamashita T; Budhu A; Forgues M; Wang XW
    Cancer Res; 2007 Nov; 67(22):10831-9. PubMed ID: 18006828
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Wnt signaling and telomerase activation of hepatoblastoma: correlation with chemosensitivity and surgical resectability.
    Ueda Y; Hiyama E; Kamimatsuse A; Kamei N; Ogura K; Sueda T
    J Pediatr Surg; 2011 Dec; 46(12):2221-7. PubMed ID: 22152854
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of the genes chemosensitizing hepatocellular carcinoma cells to interferon-α/5-fluorouracil and their clinical significance.
    Sakabe T; Tsuchiya H; Kanki K; Azumi J; Gonda K; Mizuta Y; Yamada D; Wada H; Shomori K; Nagano H; Shiota G
    PLoS One; 2013; 8(2):e56197. PubMed ID: 23457527
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MicroRNA-21 induces resistance to the anti-tumour effect of interferon-α/5-fluorouracil in hepatocellular carcinoma cells.
    Tomimaru Y; Eguchi H; Nagano H; Wada H; Tomokuni A; Kobayashi S; Marubashi S; Takeda Y; Tanemura M; Umeshita K; Doki Y; Mori M
    Br J Cancer; 2010 Nov; 103(10):1617-26. PubMed ID: 20978511
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PROX1 promotes hepatocellular carcinoma proliferation and sorafenib resistance by enhancing β-catenin expression and nuclear translocation.
    Liu Y; Ye X; Zhang JB; Ouyang H; Shen Z; Wu Y; Wang W; Wu J; Tao S; Yang X; Qiao K; Zhang J; Liu J; Fu Q; Xie Y
    Oncogene; 2015 Oct; 34(44):5524-35. PubMed ID: 25684142
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pegylated interferon alpha targets Wnt signaling by inducing nuclear export of β-catenin.
    Thompson MD; Dar MJ; Monga SP
    J Hepatol; 2011 Mar; 54(3):506-12. PubMed ID: 21093092
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dimeric oxyberberine CT4-1 targets LINC02331 to induce cytotoxicity and inhibit chemoresistance via suppressing Wnt/β-catenin signaling in hepatocellular carcinoma.
    Lin X; Chen J; Li X; Chen D; Luo K; Deng Y; Yang D; Huang Z; Tao C
    Arch Toxicol; 2023 Jun; 97(6):1627-1647. PubMed ID: 37120773
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of the Fas/FasL pathway in combination therapy with interferon-alpha and fluorouracil against hepatocellular carcinoma in vitro.
    Nakamura M; Nagano H; Sakon M; Yamamoto T; Ota H; Wada H; Damdinsuren B; Noda T; Marubashi S; Miyamoto A; Takeda Y; Umeshita K; Nakamori S; Dono K; Monden M
    J Hepatol; 2007 Jan; 46(1):77-88. PubMed ID: 17045692
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of interferon-alpha and 5-fluorouracil inhibits endothelial cell growth directly and by regulation of angiogenic factors released by tumor cells.
    Wada H; Nagano H; Yamamoto H; Noda T; Murakami M; Kobayashi S; Marubashi S; Eguchi H; Takeda Y; Tanemura M; Umeshita K; Doki Y; Mori M
    BMC Cancer; 2009 Oct; 9():361. PubMed ID: 19821965
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination therapy of intra-arterial 5-fluorouracil and systemic pegylated interferon α-2b for advanced hepatocellular carcinoma.
    Kasai K; Ushio A; Kasai Y; Sawara K; Miyamoto Y; Oikawa K; Kuroda H; Takikawa Y; Suzuki K
    Int J Clin Oncol; 2011 Jun; 16(3):221-9. PubMed ID: 21132451
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genes associated with human hepatocellular carcinoma cell chemosensitivity to 5-fluorouracil plus interferon-alpha combination chemotherapy.
    Moriyama M; Hoshida Y; Kato N; Otsuka M; Yoshida H; Kawabe T; Omata M
    Int J Oncol; 2004 Nov; 25(5):1279-87. PubMed ID: 15492816
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interferon-α2b and transforming growth factor-β1 treatments on HCC cell lines: Are Wnt/β-catenin pathway and Smads signaling connected in hepatocellular carcinoma?
    Ceballos MP; Parody JP; Alvarez Mde L; Ingaramo PI; Carnovale CE; Carrillo MC
    Biochem Pharmacol; 2011 Dec; 82(11):1682-91. PubMed ID: 21843516
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Wnt receptor FZD1 mediates chemoresistance in neuroblastoma through activation of the Wnt/beta-catenin pathway.
    Flahaut M; Meier R; Coulon A; Nardou KA; Niggli FK; Martinet D; Beckmann JS; Joseph JM; Mühlethaler-Mottet A; Gross N
    Oncogene; 2009 Jun; 28(23):2245-56. PubMed ID: 19421142
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MiR-27a modulates the MDR1/P-glycoprotein expression by inhibiting FZD7/β-catenin pathway in hepatocellular carcinoma cells.
    Chen Z; Ma T; Huang C; Zhang L; Lv X; Xu T; Hu T; Li J
    Cell Signal; 2013 Dec; 25(12):2693-701. PubMed ID: 24018051
    [TBL] [Abstract][Full Text] [Related]  

  • 19. WM130 preferentially inhibits hepatic cancer stem-like cells by suppressing AKT/GSK3β/β-catenin signaling pathway.
    Ni CX; Qi Y; Zhang J; Liu Y; Xu WH; Xu J; Hu HG; Wu QY; Wang Y; Zhang JP
    Oncotarget; 2016 Nov; 7(48):79544-79556. PubMed ID: 27783993
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The monoclonal antibody CH12 augments 5-fluorouracil-induced growth suppression of hepatocellular carcinoma xenografts expressing epidermal growth factor receptor variant III.
    Jiang H; Dong Q; Luo X; Shi B; Wang H; Gao H; Kong J; Zhang J; Li Z
    Cancer Lett; 2014 Jan; 342(1):113-20. PubMed ID: 24007863
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.